Arrowhead Pharmaceuticals (ARWR) stock gains as company reassures investors about financial obligations required from Sarepta ...

Sarepta Therapeutics (SRPT) stock is downgraded at Bank of America based on safety concerns related to the company's Elevidys gene therapy for Duchenne. Read more here.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2025.. "In the first quarter, we achieved net product ...

We note that Sarepta Therapeutics, Inc. (NASDAQ:SRPT) does have debt on its balance sheet. But the real question is whether this debt is making the company risky. When Is Debt Dangerous?

Sarepta Therapeutics Inc. (NASDAQ: SRPT) jumped nearly 31% on May 15, after a Food and Drug Administration committee gave a thumbs up to the company’s experimental gene therapy to treat Duchenne ...

We expect Sarepta Therapeutics SRPT to beat expectations when it reports fourth-quarter and full-year 2023 results. In the last reported quarter, the company delivered an earnings surprise of 72.29%.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS, the only approved gene therapy for patients with Duchenne ...

Shares of Sarepta Therapeutics SRPT have surged 76.8% in the past three months compared with the industry’s 10.2% rise. Sarepta’s commercial portfolio consists of three RNA-based PMO therapies ...

The stock price of Sarepta Therapeutics (NASDAQ:SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases ...

High-rolling investors have positioned themselves bullish on Sarepta Therapeutics (NASDAQ:SRPT), and it's important for retail traders to take note. \This activity came to our attention today ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) insiders who purchased shares in the last 12 months were richly rewarded last week. The stock climbed by 5.3% resulting in a US$375m addition to the ...

CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the ...